SG10201600234PA - Pluripotent Stem Cells Obtained By Non-Viral Reprogramming - Google Patents

Pluripotent Stem Cells Obtained By Non-Viral Reprogramming

Info

Publication number
SG10201600234PA
SG10201600234PA SG10201600234PA SG10201600234PA SG10201600234PA SG 10201600234P A SG10201600234P A SG 10201600234PA SG 10201600234P A SG10201600234P A SG 10201600234PA SG 10201600234P A SG10201600234P A SG 10201600234PA SG 10201600234P A SG10201600234P A SG 10201600234PA
Authority
SG
Singapore
Prior art keywords
stem cells
pluripotent stem
cells obtained
viral reprogramming
reprogramming
Prior art date
Application number
SG10201600234PA
Inventor
James Thomson
Junying Yu
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201600234P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of SG10201600234PA publication Critical patent/SG10201600234PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG10201600234PA 2008-10-24 2009-10-23 Pluripotent Stem Cells Obtained By Non-Viral Reprogramming SG10201600234PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10836208P 2008-10-24 2008-10-24

Publications (1)

Publication Number Publication Date
SG10201600234PA true SG10201600234PA (en) 2016-02-26

Family

ID=41698343

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201600234PA SG10201600234PA (en) 2008-10-24 2009-10-23 Pluripotent Stem Cells Obtained By Non-Viral Reprogramming

Country Status (10)

Country Link
US (4) US8268620B2 (en)
EP (2) EP2356221B1 (en)
JP (5) JP2012506702A (en)
CN (2) CN102239249A (en)
CA (1) CA2741090C (en)
DK (2) DK2356221T3 (en)
ES (1) ES2959327T3 (en)
IL (1) IL212433B (en)
SG (1) SG10201600234PA (en)
WO (1) WO2010048567A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018039B1 (en) * 2005-12-13 2013-05-30 Киото Юниверсити Nuclear reprogramming factor
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8440461B2 (en) 2007-03-23 2013-05-14 Wisconsin Alumni Research Foundation Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
WO2009133971A1 (en) * 2008-05-02 2009-11-05 Kyoto University Method of nuclear reprogramming
ES2587395T3 (en) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedures for the production of IPS cells using a non-viral approach
EP3330371A1 (en) * 2008-08-12 2018-06-06 Cellular Dynamics International, Inc. Methods for the production of ips cells
WO2010048567A1 (en) * 2008-10-24 2010-04-29 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
CN105925535A (en) 2009-06-05 2016-09-07 细胞动力国际有限公司 Method Of Reprogramming T Cells And Hematopoietic Cells
US8048675B1 (en) * 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
EP3382008A1 (en) 2010-06-15 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
BR112013002811A8 (en) * 2010-08-05 2020-01-28 Wisconsin Alumni Res Found simplified basic means for human pluripotent cell culture
US9279107B2 (en) 2010-08-05 2016-03-08 Wisconsin Alumni Research Foundation Simplified basic media for human pluripotent cell culture
EP2616554A1 (en) 2010-09-17 2013-07-24 President and Fellows of Harvard College Functional genomics assay for characterizing pluripotent stem cell utility and safety
US9133266B2 (en) 2011-05-06 2015-09-15 Wisconsin Alumni Research Foundation Vitronectin-derived cell culture substrate and uses thereof
EP2732029B1 (en) * 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Methods for cell reprogramming and genome engineering
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP2788033B1 (en) 2011-12-05 2017-05-31 Factor Bioscience Inc. Methods and products for transfecting cells
WO2013090919A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
US20130266541A1 (en) * 2012-04-06 2013-10-10 The Johns Hopkins University Human induced pluripotent stem cells
CN104769112A (en) 2012-11-01 2015-07-08 菲克特生物科学股份有限公司 Methods and products for expressing proteins in cells
EP3323884A1 (en) 2013-02-01 2018-05-23 The United States Of America as Represented by the Secretary, Department of Health an Human Service Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
EP3008229B1 (en) 2013-06-10 2020-05-27 President and Fellows of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
KR101551926B1 (en) 2013-09-06 2015-09-10 가톨릭대학교 산학협력단 Human induced pluripotent stem cells and method for producing animal expressed human immune system using the same
US11377639B2 (en) 2013-11-15 2022-07-05 Wisconsin Alumni Research Foundation Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors
MX2016009771A (en) 2014-01-31 2016-11-14 Factor Bioscience Inc Methods and products for nucleic acid production and delivery.
US20170044500A1 (en) 2014-04-24 2017-02-16 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3215168B1 (en) * 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP6873898B2 (en) * 2015-04-14 2021-05-19 国立大学法人京都大学 A method for producing a stem cell clone suitable for inducing differentiation into somatic cells
JP6449138B2 (en) 2015-07-02 2019-01-09 株式会社豊田中央研究所 Method for inducing genetic recombination and use thereof
US20190169569A1 (en) 2015-09-08 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
ES2903442T3 (en) 2015-09-08 2022-04-01 Fujifilm Cellular Dynamics Inc MACS-based purification of stem cell-derived retinal pigment epithelium
CN105219729B (en) * 2015-09-28 2018-09-25 首都医科大学宣武医院 A kind of method and application thereof using nonconformity plasmid vector induced nerve stem cells
WO2017070337A1 (en) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
WO2017196175A1 (en) 2016-05-12 2017-11-16 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium.
CN105861447B (en) * 2016-06-13 2017-12-19 广州市搏克生物技术有限公司 A kind of non-viral iPSCs inducing compositions and its kit
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
CA3029582A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
WO2018026723A1 (en) 2016-08-01 2018-02-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
WO2018035377A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN110050061A (en) 2016-10-05 2019-07-23 富士胶片细胞动力公司 The mature pedigree of generation is induced multi-potent stem cell from what is destroyed with MeCP2
EP3538168A1 (en) 2016-11-09 2019-09-18 The United States of America, as represented by The Secretary, Department of Health and Human Services 3d vascularized human ocular tissue for cell therapy and drug discovery
US11530388B2 (en) 2017-02-14 2022-12-20 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
MX2019011897A (en) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells.
US11572544B2 (en) 2017-06-14 2023-02-07 The Children's Medical Center Corporation Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer
US10760057B2 (en) 2017-07-06 2020-09-01 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
US20190100730A1 (en) 2017-10-03 2019-04-04 Wallkill BioPharma, Inc. Treating diabetes with genetically modified beta cells
AU2019256723A1 (en) 2018-04-20 2020-11-05 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
AU2019336221A1 (en) 2018-09-07 2021-03-04 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
JP2022513073A (en) 2018-11-19 2022-02-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Biodegradable tissue replacement implants and their use
CA3121027A1 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
EP3886874A1 (en) 2018-11-29 2021-10-06 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4118234A1 (en) 2020-03-09 2023-01-18 FUJIFILM Corporation Markers specific for pluripotent stem cells, and methods of using the same
IL298085A (en) 2020-05-29 2023-01-01 Fujifilm Cellular Dynamics Inc Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
US20230212509A1 (en) 2020-05-29 2023-07-06 FUJIFILM Cellular Dynamics, Inc. Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
BR112023018844A2 (en) 2021-04-07 2023-10-10 Century Therapeutics Inc COMPOSITIONS AND METHODS FOR GENERATION OF GAMMA-DELTA T CELLS FROM INDUCED PLURIPOTENT STEM CELLS
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
EP4347796A1 (en) 2021-05-26 2024-04-10 Fujifilm Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
CA3220433A1 (en) 2021-05-28 2022-12-01 Arvydas Maminishkis Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
EP4347795A1 (en) 2021-05-28 2024-04-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
CA3231501A1 (en) 2021-09-13 2023-03-16 Steven Kattman Methods for the production of committed cardiac progenitor cells
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
IL147990A0 (en) * 1999-08-05 2002-09-12 Mcl Llc Multipotent adult stem cells and methods for isolation
AU2004211654B2 (en) 2003-02-07 2009-03-05 Wisconsin Alumni Research Foundation Directed genetic modifications of human stem cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8440461B2 (en) * 2007-03-23 2013-05-14 Wisconsin Alumni Research Foundation Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
CN101250502A (en) * 2008-04-01 2008-08-27 中国科学院上海生命科学研究院 Method for preparing evoked pluripotent stem cell
WO2009133971A1 (en) 2008-05-02 2009-11-05 Kyoto University Method of nuclear reprogramming
ES2587395T3 (en) * 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedures for the production of IPS cells using a non-viral approach
WO2009157201A1 (en) * 2008-06-26 2009-12-30 Osaka University Method and kit for preparing ips cells
WO2010012077A1 (en) * 2008-07-28 2010-02-04 Mount Sinai Hospital Compositions, methods and kits for reprogramming somatic cells
WO2010048567A1 (en) * 2008-10-24 2010-04-29 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming

Also Published As

Publication number Publication date
ES2959327T3 (en) 2024-02-23
JP2018174945A (en) 2018-11-15
CA2741090A1 (en) 2010-04-29
WO2010048567A1 (en) 2010-04-29
JP6861189B2 (en) 2021-04-21
DK3450545T3 (en) 2023-10-02
EP2356221B1 (en) 2018-11-21
US20130217117A1 (en) 2013-08-22
EP3450545B1 (en) 2023-08-23
DK2356221T3 (en) 2019-02-18
JP7165228B2 (en) 2022-11-02
US8268620B2 (en) 2012-09-18
US20190330654A1 (en) 2019-10-31
IL212433B (en) 2019-08-29
EP3450545A1 (en) 2019-03-06
CA2741090C (en) 2018-10-16
US20100184227A1 (en) 2010-07-22
US20220010331A1 (en) 2022-01-13
IL212433A0 (en) 2011-06-30
JP6312638B2 (en) 2018-04-18
JP2012506702A (en) 2012-03-22
CN102239249A (en) 2011-11-09
JP2015213522A (en) 2015-12-03
EP2356221A1 (en) 2011-08-17
CN105802917A (en) 2016-07-27
JP2021094040A (en) 2021-06-24
JP2016220686A (en) 2016-12-28

Similar Documents

Publication Publication Date Title
IL212433A0 (en) Pluripotent stem cells obtained by non-viral reprogramming
ZA201606403B (en) Pluripotent stem cell culture on micro-carriers
HK1216883A1 (en) Stem cell cultures
SG10201500674YA (en) Pluripotent stem cells
EP2315829A4 (en) Induced pluripotent stem cells
ZA201008391B (en) Pluripotent cells
EP2414510A4 (en) Induced pluripotent stem cells
EP2145000A4 (en) Reprogramming of somatic cells
IL247310B (en) Mesenchymal stem cell differentiation
ZA201000715B (en) Single pluripotent stem cell culture
GB0814249D0 (en) Uses of mesenchymal stem cells
HK1201295A1 (en) Abc5 positive mesenchymal stem cells as immunomodulators abc5
EP2601290A4 (en) Somatic stem cells
EP2294182A4 (en) Multipotent stem cell cultures
EP2446020A4 (en) Dental stem cell reprogramming
GB0919773D0 (en) Induced pluripotent stem cell
GB0900845D0 (en) Reprogramming cells
GB0813770D0 (en) Reprogramming cells
GB0815496D0 (en) Reprogramming cells
GB0818256D0 (en) stem cells
GB0901069D0 (en) Stem cell culture methods
GB0916476D0 (en) Stem cell culture methods
GB0918471D0 (en) Stem cells
ZA200907185B (en) Reprogramming of somatic cells